Quantcast

Latest Alitretinoin Stories

2014-02-18 23:26:46

MarketResearchReports.Biz announces addition of new report “AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014” to its database. Visit: http://www.marketresearchreports.biz/analysis/187350. Albany, NY (PRWEB) February 18, 2014 Global Markets Directs, 'AIDS Related Kaposi's Sarcoma Pipeline Review, H1 2014', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for AIDS Related Kaposi's...

2008-11-13 03:00:16

Basilea Pharmaceutica Ltd. announces that ceftobiprole (Zevtera(TM)), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections. Dr. Anthony Man, CEO of Basilea said, "We are delighted by this approval of ceftobiprole by Swissmedic. This is an important moment for our company and brings a novel and effective treatment against resistant...

2008-10-27 03:00:36

Basel, Switzerland, October 27, 2008 - Multi-resistant Gram-negative bacteria are causing increasing concern around the world. Basilea's novel antibiotic BAL30072 demonstrates potent in-vitro activity against some of the most difficult to treat multi-resistant Gram-negative bacteria. Basilea Pharmaceutica's Head of Biology, Prof. Malcolm Page, presented in vitro data on Basilea's novel antibiotic BAL30072 at the Poster Review Session of the joint meeting of the Annual Interscience...

2008-10-21 03:00:19

Basel, Switzerland, October 21, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino(R) (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the French Health Products Safety Agency (Agence Francaise de Securite Sanitaire des Produits de Sante [AFSSAPS]). Following the recommendation for regulatory approval under the European decentralized procedure, Toctino(R) has received...

2008-10-20 03:00:08

Basel, Switzerland, October 20, 2008 - New data on Basilea's late-stage anti-infectives ceftobiprole and isavuconazole will be presented at the upcoming joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA) in Washington DC. A series of more than twenty presentations related to ceftobiprole, a broad-spectrum anti-MRSA cephalosporin antibiotic, will be discussed at ICAAC/IDSA. The...

2008-10-15 03:00:22

Basilea Pharmaceutica Ltd. announces that Toctino(R) (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by Finland's National Agency for Medicines (NAM). Following the recommendation for regulatory approval under the European decentralized procedure, Toctino(R) received national regulatory approval in Finland. Following the regulatory approval of Toctino(R) in Finland, Basilea...

2008-10-06 03:00:29

Basel, Switzerland, October 6, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino(R) (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the German health authority "Bundesinstitut fuer Arzneimittel und Medizinprodukte" (BfArM). Following the recommendation for regulatory approval under the European decentralized procedure, Toctino(R) received national regulatory approval...

2008-09-22 03:00:30

Basilea Pharmaceutica Ltd. announces that Toctino(R) (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Danish Medicines Agency (DKMA). Following the recommendation for regulatory approval under the European decentralized procedure, Toctino(R) received national regulatory approval in Denmark. Marketing applications for the use of alitretinoin in the treatment of severe...

2008-09-08 03:00:25

Basel, Switzerland, September 8, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino(R) (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Following the recommendation for regulatory approval under the European decentralized procedure, Toctino(R) received its first national regulatory...

2008-07-31 03:00:43

Basel, Switzerland, July 31, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino(R) (alitretinoin), a new oral therapy for severe refractory Chronic Hand Eczema (CHE), was recommended for regulatory approval under the European decentralized procedure and will become the first authorized treatment for this chronic disabling disease. The concerned EU Member States concluded that the profile of Toctino(R) (alitretinoin) is favorable for the use in adults who suffer from severe CHE that is...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.